Short-Chain Fatty Acid Receptor and Its Contribution to Glucagon-Like Peptide-1 Release

Izumi Kaji\textsuperscript{a,b}  Shin-ichiro Karaki\textsuperscript{b}  Atsukazu Kuwahara\textsuperscript{b}

\textsuperscript{a}Laboratory of Histology and Cytology, Graduate School of Medicine, Hokkaido University, Sapporo, and
\textsuperscript{b}Laboratory of Physiology, Institute for Environmental Sciences, University of Shizuoka, Shizuoka, Japan

**Key Words**
Luminal chemosensing · Short-chain fatty acid receptor · Enteroendocrine L cell · Glucagon-like peptide-1

**Abstract**

**Background:** Gut microbiota affects host homeostasis and dysbiosis causes host diseases. Therefore, uncovering the sensing mechanism of bacterial metabolites such as short-chain fatty acid (SCFA) may help us to understand the host-microbiota interaction both in physiological and nonphysiological conditions. **Summary:** The colonic lumen is continually exposed to many kinds of chemicals, including beneficial and harmful compounds that are produced by gut microbiota in addition to ingested nutrients. In the mammalian colon SCFAs such as acetate, propionate and butyrate are produced by bacterial fermentation and reach about 100 mM under physiological conditions. In this decade, SCFA receptor genes and their expression in the intestine have been identified as free fatty acid receptor (FFA)\textsubscript{2} and FFA\textsubscript{3}. The FFAs are located in colonic enteroendocrine L cells producing and releasing an insulinotropic hormone, glucagon-like peptide-1 (GLP-1), and an anorectic hormone, peptide YY. Recent in vivo and in vitro studies suggest that SCFAs stimulate gut hormone secretion. Therefore, the SCFA-FFA signal is likely to be important for gut physiological functions. **Key Message:** Colonic epithelial cells express chemical receptors that detect the luminal contents, particularly bacterial metabolites, and may be involved in the host’s energy metabolism via GLP-1 release, as well as the mucosal defense system.

© 2014 S. Karger AG, Basel

**Introduction**

The gut lumen is open to the external environment and it has approximately 100 trillion archael and bacterial cells. This means that gut microbiota contains a huge amount of genetic information; it is estimated to contain 100- to 400-fold more genes than the human genome. From this genetic point of view, gut microbiota has a large capacity to produce various kinds of metabolites controlled by their genes. The bacterial products include beneficial and harmful compounds for the host and affect many aspects of the host’s condition. Indeed, microbiota dysfunction is linked to a variety of disorders, namely obesity, type 1 and type 2 diabetes, irritable bowel syndrome, colonic cancer, inflammatory bowel disease and abnormal immune response \cite{1}. Furthermore, the integral role of gut microbiota in the regulation of the host’s energy metabolism has also been indicated. However, mechanistic insights are obscure, and it is still unknown whether dysbiosis has a causal role in the pathogenesis of the above-mentioned diseases.

Since intestinal epithelia function as ‘sentinel’ to recognize beneficial or harmful compounds for the internal environment, the epithelia form a heterologous barrier sheet between the internal and luminal (external) environments. In cooperation with the epithelial sheet – consisting of absorptive, goblet, M, enteroendocrine and brush cells – lamina propria cells and nerve fibers, which lie close to the epithelial cells but lack direct contact with the lumen, act together to balance nutrient absorption.
and host-defense activities. Recent membrane receptor characterization indicates that enteroendocrine cells in particular serve important roles as sensors both in local and systemic signal transductions through gut hormone releases. One type of enteroendocrine cell is the L cell, which produces and releases glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Since GLP-1 is an insulinotropic gut hormone and PYY is an anorectic gut hormone, they are implicated in systemic energy metabolism and metabolic dysfunction. In addition, L cells are relatively concentrated in the terminal ileum and colon. While chemosensory mechanisms in the small intestine are well studied in conjunction with nutrient absorption, much less is known about this in the large intestine. In the mammalian colon, short-chain fatty acids (SCFAs) are present at high concentration due to bacterial fermentation and stimulate a variety of gut functions. Therefore, SCFA is considered to be one of the chemical mediators to link luminal information between microbiota and the host through SCFA receptors located in the intestinal epithelia. This mini review will focus on new information about SCFA receptors and their possible role in GLP-1 secretion in the colon.

SCFA Sensing in the Colon

As an important energy source for colonocytes, SCFA is detected and implicated in colonic homeostasis. In nonruminant mammals, SCFAs are produced by microbiota in the distal small intestine and colon from low-digestible carbohydrates, including resistant starch and soluble oligo- and poly-saccharides. The main components of SCFAs in the human colon are acetate (2-carbon), propionate (3-carbon) and butyrate (4-carbon), at a ratio of about 3:1:1 [2]. Once produced, about 90% of SCFAs are readily absorbed by colonocytes; butyrate in particular is almost entirely utilized by colonocytes [3]. Absorbed propionate is primarily removed from the portal vein by the liver [4]. Peripheral blood levels of butyrate and propionate are therefore low under physiological conditions at 1–3 μM butyrate and 4–5 μM propionate. Acetate, however, passes more freely into the peripheral circulation and shows high plasma levels of up to 100–150 μM [5], and this concentration can be increased up to 250% (250–400 μM) following the hepatic breakdown of ingested ethanol [6]. On the other hand, a much higher concentration of SCFAs is present in the lumen of the nonruminant mammalian colon; the concentration volatiles depending upon bacterial activity, but it is usually about 100 mM [4]. Therefore, in addition to an instant energy source, SCFAs have been proposed as key signaling molecules in local and remote physiological functions such as transepithelial anion secretion, intestinal motility and systemic energy metabolism. In 1988, Yajima [7] reported the effect of SCFAs on rat colonic secretion using the Ússing chamber technique. Luminal, but not basolateral application of butyrate or propionate induces transient Cl− secretion into the lumen through the Gq/11 and cholinergic pathway even in the muscular and submucosa-stripped mucosa preparations [8]. The results indicate the presence of certain sensory devices in the luminal side.

In 2003, the G protein-coupled receptors, GPR43 and GPR41, were deorphanized as receptors for SCFAs [9–11], and have since been renamed as free fatty acid receptor (FFA)2 and FFA3, respectively [12] (table 1). Acetate preferentially activates human FFA2 in vitro, propionate is an even agonist for FFA2 and FFA3 and butyrate preferentially activates FFA3. However, mice FFA2 and FFA3 showed a slightly different nature – both of them responded to acetate and butyrate at the same level, but FFA3 was more sensitive to propionate than FFA2 [13], suggesting the species heterogeneity in the ligand potency for FFAs. The activation of these receptors affects distinct functions depending on the cell types expressing the receptors. For example, SCFAs suppress inflammation through FFA2 signaling in immune cells, such as neutrophil, and modulate the secretion of GLP-1 – which improves insulin secretion and has an antidiabetic effect – by enteroendocrine L cells in the distal small intestine and colon [14]. Whilst the two receptors share endogenous ligands, their G-protein signaling mechanisms differ from each other. FFA2 and FFA3 can both signal through the pertussis toxin-sensitive Gq/11 pathway, whilst FFA2 possesses the ability to signal through the Gq/11 pathway. The physiological significance of this dual-coupling mechanism in FFA2 is not yet understood. Messenger RNA (mRNA) for FFA2 was detected in the extracts from separated mucosa of rat distal ileum and colon [15]. In human ascending colon, mRNA for FFA2 was also detected in the extracts from separated mucosa, but not from the submucosa and muscle layer [16]. These results indicate that FFA2 is expressed by colonic mucosa, but not by enteric neurons or smooth muscle cells. Since mRNA expression of FFA2 was abundant compared with FFA3 in all parts of the rat large intestine [8], FFA2-Gq/11 signaling is likely to be a predominant pathway in colonic secretion. Until 2009, there was no report of FFA3 expression in the gut. Recently, we found that
FFA3 protein and mRNA were expressed in human colonic mucosa and that the expression levels were higher in the mucosa than in the submucosa and muscle layer [17].

To identify the cellular distribution of FFA2 and FFA3 in the rat and human colon, we performed an immunohistochemical study. We demonstrated that FFA2 was expressed in rat, guinea pig and human colonic epithelial cells with particularly strong expression in PYY- and GLP-1-producing L cells [15, 16, 18, 19] (fig. 1). Immunoreactivity for FFA2 in laboratory animals showed a similar pattern to those in the human colon. FFA2-immunoreactive L cells in the colon were open-type enteroendocrine cells, which extended their cell body to the luminal surface. FFA3 was also detected in human colonic L cells [17], but it is still unclear whether these two receptors function in the same cells. FFA3-immunoreactive L cells in the human colon were also open type [17]. These morphological studies indicate that PYY- and GLP-1-containing L cells expressing SCFA receptors are chemosensory cells and that activation of FFA2 and FFA3 by luminal SCFAs may regulate PYY and/or GLP-1 secretion. However, further studies are needed to clarify the precise distribution pattern of FFA2 and FFA3 and the direct evidence that link FFAs to gut hormone secretion in situ for understanding the physiological function of these receptors.

### Dietary Fiber Affects Colonic Enteroendocrine Cell Populations and FFA2 Expression through SCFA Production

Long-term ingestion of fermentable dietary fibers increases luminal concentrations of SCFAs [20]. Therefore, we have examined whether long-term ingestion of fructooligosaccharide (FOS) affects density or expression patterns of FFAs. Dietary supplementation with FOS for 4 weeks increased the density of L cells expressing FFA2 and GLP-1 by approximately 2-fold in the rat proximal colon, but did not affect the fecal content or density of enterochromaffin (EC) cells producing 5-HT [19] (fig. 2). By contrast, dietary supplementation with cellulose, an insoluble dietary fiber, greatly increased fecal content and the density of EC cells in the rat colon compared with those in rats fed a fiber-free diet [21]. These findings suggest that the increase in luminal SCFA concentration induces L cell proliferation, and that the increase in luminal content volume induces EC cell proliferation. This is supported by the following observation that supplementation with oligofructose upregulates the expression of neurogenin 3 and NeuroD, two factors that promote differentiation of enteroendocrine cells [22]. Other studies have also reported that SCFA supply to total parenteral nutrition feeding for periods of 6–72 h increased proglucagon mRNA in rat ileum [23]. Therefore, the increase in GLP-1-containing L cells

<table>
<thead>
<tr>
<th>Nomenclature</th>
<th>Other names</th>
<th>G proteins</th>
<th>Effectors</th>
<th>Organic agonists</th>
<th>Major expression cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>FFA1</td>
<td>GPR40</td>
<td>$G_{q/11}$</td>
<td>$Ca^{2+}$↑</td>
<td>Medium- to long-chain fatty acids, saturated (C10–C18)/unsaturated (C18–C22)</td>
<td>Pancreatic β cells Enteroendocrine K cells</td>
</tr>
<tr>
<td>FFA2</td>
<td>GPR43</td>
<td>$G_{q/o}$</td>
<td>cAMP ↓</td>
<td>SCFAs (C2–C7) Acetate = propionate = butyrate</td>
<td>Immune cells Enteroendocrine L cells</td>
</tr>
<tr>
<td>FFA3</td>
<td>GPR41</td>
<td>$G_{q/11}$</td>
<td>$Ca^{2+}$↑</td>
<td>SCFAs (C2–C7) Propionate = butyrate &gt; acetate</td>
<td>Adipocytes Enteroendocrine L cells</td>
</tr>
<tr>
<td>FFA4</td>
<td>GPR120</td>
<td>$G_{q/11}$</td>
<td>cAMP ↓</td>
<td>Long-chain fatty acid, saturated (C14–C18)/unsaturated (C16–C22)</td>
<td>Enteroendocrine L cells</td>
</tr>
<tr>
<td>GPR84</td>
<td></td>
<td>$G_{q/o}$</td>
<td>cAMP ↓</td>
<td>Medium-chain fatty acids (C9–C14)</td>
<td>Immune cells</td>
</tr>
<tr>
<td>GPR109A</td>
<td>HM74A</td>
<td>$G_{q/o}$</td>
<td>cAMP ↓</td>
<td>SCFAs (C4–C8) Nicotinate</td>
<td>Adipocytes Macrophages Intestinal epithelial cells</td>
</tr>
</tbody>
</table>

Table 1. Fatty acid receptors

SCFA Receptor and Its Contribution to GLP-1 Release

Digestion 2014;89:31–36
DOI: 10.1159/000356211
by ingested dietary fiber would be of benefit, particularly for antiobesity, since GLP-1 reduces food intake [24].

**Possible Role of SCFAs in GLP-1 Secretion**

Some in vivo studies have demonstrated that intraluminal injection of SCFAs induced the release of PYY and GLP-1 into plasma [25, 26]. Since GLP-1 secreting L cells are mainly located in the distal small intestine and colon, and the primary site of SCFA production is the colon, it is important to know whether luminal SCFA in the colon induces GLP-1 release into the subepithelial space in the tissue level. Therefore, we measured the GLP-1 release response to luminal application of SCFA using an Üssing chamber. In the muscle-stripped mucosa-submucosal preparations, luminal application of 5 mM propionate induced GLP-1 release into the basolateral side (fig. 3). Since SCFA concentration in the colonic lumen reaches higher millimole per liter (mM) levels, the dose of propionate in our study is in the physiological range. Consistent with these observations, the fluorescent-based cell sorting technique demonstrated that murine colonic L cells expressed both FFA2 and FFA3, and acetate and propionate increased the intracellular calcium level causing GLP-1 release via $G_{q/11}$, but not $G_i$ [14]. The basal GLP-1 level in FFA2 knockout mice was significantly lower than in the wild-type, suggesting that FFA2 mainly contributes to GLP-1 produc-
tion and/or release in the murine colon [14]. On the other hand, individual FFA2- or FFA3-deficient mice showed low GLP-1 release in response to SCFAs, indicating that FFA3 is also involved in SCFA-evoked GLP-1 release [14, 27]. High-dose (80 mM) acetate-evoked GLP-1 releases were also observed in the isolated colonic mucosa from wild-type mice, but not from α-gustducin knockout mice [28]. As gustducin is a Gi family member, the possibility was raised that Gi-coupled FFA2 and/or FFA3 elicit GLP-1 releases in the colon. Inconsistent with data from humans and rodents, none of the SCFAs (C2–C6, 5 mM) stimulate the release of GLP-1, GLP-2 or PYY from ileal and colonic tissues of porcine [29]. This might be caused by species differences in the ligand-binding potency of FFAs. Based on the current findings, luminal SCFAs are expected to stimulate FFA2 and/or FFA3 located on the colonic L cells and induce GLP-1 release, although the intracellular mechanism is not fully understood. As luminal SCFA concentrations are not predicted to be reduced markedly in response to acute food ingestion, it is possible that SCFAs produced by colonic bacterial fermentation provide a chronic stimulatory tone on L cells via SCFA receptors under physiological conditions. The tonic stimulation of GLP-1 secretion may chronically affect the systemic energy metabolism, because GLP-1 releases are suppressed in obese subjects [30]. If GLP-1 release could be enhanced via FFA2 and FFA3 activation, the potential for dietary or pharmacological manipulation to increase satiety could be used in the treatment of obesity in the future.

**Conclusion**

Since obesity and metabolic disorders are associated with changes in gut microbiota, the integral role of gut microbiota in the regulation of host energy metabolism has attracted considerable attention [31]. However, because of the complexity of the microbial community, the functional connections between dysbiosis and human diseases are less well understood. SCFAs are primary metabolites of gut microbiota and present in the colon at high concentrations. SCFA sensing in the colon serves two important functions – the energy survey and the mucosal defense against microbial pathogenicity. We have shown that the SCFA receptors FFA2 and FFA3 are located in rodent and human colonic L cells containing GLP-1 and PYY, suggesting that FFA2 and/or FFA3 may be implicated in the host energy metabolism through PYY and GLP-1 releases. Furthermore, we have demonstrated that luminal application of SCFA evokes GLP-1 release and that long-term ingestion of FOS influences the density of FFA2-expressing L cells. Although the re-
References


Disclosure Statement

The authors have no conflicts of interest to declare.

Kaji/Karaki/Kuwahara